Evidence map›Paper›PMID 40389720›Full record

ReviewCellular and molecular neurobiology2025

Exploring α-Syn's Functions Through Ablation Models: Physiological and Pathological Implications.

Anjali Praveen, Godfried Dougnon, Hideaki Matsui

Abstract readReview
In one paragraph

Review in Cellular and molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Anjali PraveenDepartment of Neuroscience of Disease, Brain Research Institute, Niigata University, Niigata, 951-8585, Japan.ORCID http://orcid.org/0009-0004-8012-0068
Godfried DougnonDepartment of Neuroscience of Disease, Brain Research Institute, Niigata University, Niigata, 951-8585, Japan.ORCID http://orcid.org/0000-0003-1383-5691
Hideaki MatsuiDepartment of Neuroscience of Disease, Brain Research Institute, Niigata University, Niigata, 951-8585, Japan. hide0729@bri.niigata-u.ac.jp.ORCID http://orcid.org/0000-0003-4908-1035

Funding

Japan Agency for Medical Research and Development JP23gm1710010, JP22gm6110028Japan Science and Technology Agency JPMJMS2024Japan Society for the Promotion of Science JP 23790744; JP 22484842
6 · The paper itself

Abstract

A significant advancement in neurodegenerative research was the discovery that α-synuclein (α-Syn/SNCA) plays a part in the pathophysiology of Parkinson's disease (PD). Decades later, the protein's significant impacts on various brain disorders are still being extensively explored. In disease conditions, α-Syn misfolds and forms abnormal aggregates that accumulate in neurons, thus triggering various organellar dysfunctions and ultimately neurodegeneration. These misfolded forms are highly heterogeneous and vary significantly among different synucleinopathies, such as PD, Multiple System Atrophy, or Dementia with Lewy bodies. Though initially believed to be exclusively localized in the brain, numerous pieces of evidence suggest that α-Syn functions transcend the central nervous system, with roles in peripheral functions, such as modulation of immune responses, hematopoiesis, and gastrointestinal regulation. Here, we aim to provide a detailed compilation of cellular functions and pathological phenotypes that are altered upon attenuation of α-Syn function in vitro and in vivo and explore the effects of SNCA gene silencing in healthy and disease states using cellular and animal models.

Indexed as

alpha-SynucleinAnimalsDisease Models, AnimalHumansNeuronsParkinson Diseasealpha-SynucleinAblation modelsParkinson's diseaseSNCASynucleinα-Syn

Identifiers

PMID40389720
PMCPMC12089638

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.